Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Literal federal measure citations: H.R. 7871, H.R. 5187, H.R. 7837
2026 · 3rd Quarter (July 1 - Sep 30)
BEAM THERAPEUTICS
Filed by GRIDIRON PUBLIC AFFAIRS, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $10,000.00
- Expenses
- Not reported
- Registrant
- GRIDIRON PUBLIC AFFAIRS, LLC
- Client
- BEAM THERAPEUTICS
- Filing UUID
- 661c30f5-a47a-4e3d-9c68-8713b83c25f6
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.